This dialysis stock has been on fire this year. Deutsche Bank sees more gains ahead

Deutsche Bank upgraded DaVita to Buy from Hold and raised its price target to $220 from $126, implying about 40% upside from Tuesday's close. The catalyst is improving treatment demand and better-than-expected Q1 results, including treatment growth 10 bps above consensus and revenue per treatment of $417.59, up 4.4% year over year. DaVita also guided to 20-50 bps of treatment demand growth for the year, and shares were up nearly 6% after hours.

Analysis

The important signal is not just a quarter beat; it’s that the market may be transitioning from treating dialysis as a slow secular decline story to a flat-to-up volume story with pricing support. That matters because a modest inflection in treatment growth can drive outsized earnings power in a highly fixed-cost network, so even low-single-digit unit improvement can lever margins faster than consensus expects. If management is right on sustained demand improvement, the stock’s rerating may still be early despite the strong year-to-date move.

The second-order read-through is pressure on the bearish thesis tied to GLP-1/SGLT2 substitution. Those drugs are not disappearing, but the key question is whether their kidney-protective benefits are delaying rather than permanently eliminating dialysis starts; if so, the near-term impact is a timing headwind, not a structural cap on volumes. That distinction favors the incumbent service model and likely keeps competitors in related renal care areas from assuming a durable demand shock.

Risk is concentrated in the next 1-2 quarters because the market is likely extrapolating one datapoint into a multi-year trend. The main reversal catalysts are a change in mortality/new-start mix, an earnings comp that normalizes the revenue-per-treatment rate, or evidence that the current growth is a catch-up from prior weakness rather than a stable run-rate. After a large YTD move, the trade now hinges on whether guidance revisions continue; without follow-through, upside becomes more of a valuation story than a fundamentals story.

Key Decisions for Investors

• Maintain/establish a tactical long in DVA for 1-3 months on confirmation of follow-through volume data; target another 10-15% upside if the market starts pricing a sustained operating inflection, with a tight stop if subsequent monthly/quarterly treatment growth reverts.
• Use call spreads rather than outright shares in DVA for the next earnings window (e.g., 3-6 month tenor) to express upside while limiting downside after the recent run; best risk/reward if implied volatility remains elevated but not extreme.
• Pair trade: long DVA / short a basket of healthcare names most exposed to chronic-care substitution narratives over 3-6 months; the thesis is that the market is overestimating how quickly GLP-1/SGLT2 adoption translates into dialysis volume destruction.
• If already long DVA, consider trimming 20-30% into strength and re-adding only on evidence of sustained guidance follow-through; the stock has already rerated, so marginal upside now depends on multiple expansion continuing without a fundamental miss.
• Watch for a contrarian short entry only if treatment growth decelerates back below expectations on the next print; that would quickly unwind the 'demand inflection' narrative and could pressure the stock 15%+ given the recent sentiment shift.